KRAS and familial pancreatic carcinoma: Tjensvoll et al. [76] revealed that in 14 patients with advanced pancreatic cancer receiving gemcitabine or FOLFIRINOX, positive KRAS-mutated ctDNA at baseline was significantly linked to disease progression and survival.